Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 2048-2060
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2048
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2048
Table 1 Clinicopathological characteristics of the enrolled cohort (n = 151)
Characteristic | Result |
Age diagnosis (yr) | 55.85 ± 13.26 |
Gender (%) | |
Male | 93 (61.6) |
Female | 58 (38.4) |
Distance to anal verge (cm) (%) | 4.91 ± 2.04 |
> 6 | 45 (29.8) |
≤ 6 | 106 (70.2) |
Pre-CEA (%) | |
Normal range | 98 (64.9) |
Elevated | 53 (35.1) |
Pre-T (%) | |
T1 | 2 (1.3) |
T2 | 10 (6.6) |
T3 | 133 (88.1) |
T4 | 6 (4.0) |
Pre-N (%) | |
N0 | 38 (25.2) |
N+ | 113 (74.8) |
Post-T (%) | |
pT0 | 7 (4.6) |
pT1 | 6 (4.0) |
pT2 | 48 (31.8) |
pT3 | 84 (55.6) |
pT4 | 4 (4.0) |
Post-N (%) | |
pN0 | 89 (58.9) |
pN+ | 62 (41.1) |
Tumor regression grade (%) | |
Grade 0 | 9 (6.3) |
Grade 1 | 34 (23.9) |
Grade 2 | 42 (29.6) |
Grade 3 | 57 (40.1) |
HER2 (%) | |
- | 124 (82.1) |
+ | 27 (17.9) |
LVI (%) | |
+ | 20 (13.2) |
- | 131 (86.8) |
Median follow-up period | 134 |
Distant metastasis, number (%) | |
Yes | 60 (39.7) |
No | 91 (60.3) |
Local recurrence, number (%) | |
Yes | 24 (15.9) |
No | 127 (84.1) |
Table 2 Correlations among HER2 expression and the clinicopathological parameters
Variable | HER2- (%) | HER2+ (%) | χ2 | P value |
Age (yr) | 0.558 | 0.455 | ||
< 60 | 74 (59.7) | 14 (51.9) | ||
≥ 60 | 50 (40.3) | 13 (48.1) | ||
Sex | 2.166 | 0.141 | ||
Male | 73 (58.9) | 20 (74.1) | ||
Female | 51 (41.1) | 7 (25.9) | ||
Pre-CEA | 0.045 | 0.832 | ||
Normal range | 80 (64.5) | 18 (66.7) | ||
Elevated | 44 (35.5) | 9 (33.3) | ||
Distance to anal verge (cm) | 0.236 | 0.627 | ||
> 6 | 38 (30.6) | 7 (25.9) | ||
≤ 6 | 86 (69.4) | 20 (74.1) | ||
Pre-T | 0.6941 | |||
T1-2 | 11 | 1 | ||
T3-4 | 113 | 26 | ||
Pre-N | 4.235 | 0.040 | ||
N0 | 27 (21.8) | 11 (40.7) | ||
N+ | 97 (78.2) | 16 (59.3) | ||
Post-T | 1.583 | 0.208 | ||
T1-2 | 53 | 8 | ||
T3-4 | 71 | 19 | ||
Post-N | 1.582 | 0.208 | ||
N0 | 76 (61.3) | 13 (48.1) | ||
N+ | 48 (38.7) | 14 (51.9) | ||
LVI | ||||
+ | 17 (13.7) | 3 (11.1) | 0.002 | 0.9622 |
- | 107 (86.3) | 24 (88.9) | ||
Distant metastasis | 9.959 | 0.002 | ||
+ | 42 (33.9) | 18 (66.7) | ||
- | 82 (66.1) | 9 (33.3) | ||
Local recurrence | 1.083 | 0.2982 | ||
+ | 22 (17.7) | 2 (7.4) | ||
- | 102 (82.3) | 25 (92.6) |
Table 3 Correlations among distant metastasis and the clinicopathological parameters
Variable | Distant metastasis | χ2 | P value | |
- (%) | + (%) | |||
Age (yr) | 0.121 | 0.728 | ||
< 60 | 52 (59.1) | 36 (40.9) | ||
≥ 60 | 39 (61.9) | 24 (38.1) | ||
Sex | 0.446 | 0.504 | ||
Male | 58 (62.4) | 35 (37.6) | ||
Female | 33 (56.9) | 25 (43.1) | ||
Pre-CEA | 9.704 | 0.002 | ||
Normal range | 68 (69.4) | 30 (30.6) | ||
Elevated | 23 (43.4) | 30 (56.6) | ||
Distance to anal verge (cm) | 0.103 | 0.749 | ||
> 6 | 28 (62.2) | 17 (37.8) | ||
≤ 6 | 63 (59.4) | 43 (40.6) | ||
Pre-T | 0.2211 | |||
T1-2 | 5 | 7 | ||
T3-4 | 86 | 53 | ||
Pre-N | 0.001 | 1.000 | ||
N0 | 23 (60.5) | 15 (39.5) | ||
N+ | 68 (60.2) | 45 (39.8) | ||
Post-T | 3.782 | 0.052 | ||
T1-2 | 43 | 18 | ||
T3-4 | 48 | 42 | ||
Post-N | 7.995 | 0.005 | ||
N0 | 62 (69.7) | 27 (30.3) | ||
N+ | 29 (46.8) | 33 (53.2) | ||
LVI | 1.014 | 0.314 | ||
+ | 10 (50.0) | 10 (50.0) | ||
- | 81 (61.8) | 50 (38.2) | ||
HER2, number | 9.959 | 0.002 | ||
- | 82 (66.1) | 42 (33.9) | ||
+ | 9 (33.3) | 18 (66.7) |
Table 4 Multivariate logistic regression analysis results
Variable | Odds ratio | 97.5%CI | P value |
CEA level before radiotherapy | |||
Normal range | 1 | ||
Elevated | 3.277 | 1.543-7.163 | 0.002 |
Post-treatment N | |||
N0 | 1 | ||
N+ | 2.437 | 1.143-5.308 | 0.022 |
HER2 | |||
- | 1 | ||
+ | 4.222 | 1.667-11.409 | 0.003 |
- Citation: Chen N, Li CL, Peng YF, Yao YF. Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study. World J Gastrointest Oncol 2022; 14(10): 2048-2060
- URL: https://www.wjgnet.com/1948-5204/full/v14/i10/2048.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i10.2048